{"id":362287,"date":"2024-06-12T00:00:00","date_gmt":"2024-06-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exincg0025-2024-biopharma-post-traumatic-stress-disorder-executive-insights-executive-insights-post\/"},"modified":"2026-05-10T11:20:22","modified_gmt":"2026-05-10T11:20:22","slug":"exincg0025-2024-biopharma-post-traumatic-stress-disorder-executive-insights-executive-insights-post-traumatic-stress","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exincg0025-2024-biopharma-post-traumatic-stress-disorder-executive-insights-executive-insights-post-traumatic-stress\/","title":{"rendered":"Post-Traumatic Stress Disorder &#8211; Executive Insights &#8211; Executive Insights &#8211; Post-Traumatic Stress Disorder (US)"},"content":{"rendered":"<p>Post-traumatic stress disorder (<abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>) is a chronic psychiatric condition that may emerge after a person experiences a traumatic event or series of events. Multiple guidelines recommend first treating <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of pharmacological agents. Pharmacological options for <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> are limited, with only two <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved agents, paroxetine and sertraline. Other agents, such as <abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s, mood stabilizers, and atypical antipsychotics, may be used off-label, despite limited evidence of efficacy. Additional treatment options are in late-phase development. Lykos Therapeutics\u2019 <abbr title=\"3,4-methylenedioxymethamphetamine\">MDMA<\/abbr>-assisted psychotherapy has undergone Phase 3 trials in moderate to severe <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> patients and is under <abbr title=\"Food and Drug Administration\">FDA<\/abbr> review as of June 2024. Otsuka and Lundbeck have submitted Rexulti (used in combination with sertraline) for <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval for <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>; they had previously reported positive results in one Phase 2 and one Phase 3 trial. These and other pipeline agents offer the potential for more-efficacious <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> management.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the prevalence of <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> in the United States?<\/li>\n<li>What is the treatment journey of <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> patients?<\/li>\n<li>What is the competitive landscape and the expected future influence of key emerging therapies, including <abbr title=\"3,4-methylenedioxymethamphetamine\">MDMA<\/abbr>-assisted psychotherapy and Rexulti, in <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr>?<\/li>\n<li>What are the strengths, weaknesses, drivers, and constraints of the <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> market?<\/li>\n<li>What are the key areas of unmet need and opportunities in the management of <abbr title=\"post-traumatic stress disorder\">PTSD<\/abbr> patients, according to <abbr title=\"key opinion leader\">KOL<\/abbr>s?<\/li>\n<\/ul>\n<p><strong>Product description:<\/strong><\/p>\n<p>Executive Insights provides indication-specific market intelligence withworld-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.<\/p>\n<p><strong>Release date:<\/strong> June 2024<\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary Research:<\/strong> 3 <abbr title=\"key opinion leader\">KOL<\/abbr> interviews in February 2024<\/p>\n<p><strong>Key companies covered: <\/strong>Lykos Therapeutics, Otsuka Pharmaceutical, Lundbeck, Boehringer Ingelheim, Alto Neuroscience, Compass Pathways, Bionomics<\/p>\n<p><strong>Key drugs covered:<\/strong> <abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s, <abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s, atypical antipsychotics, mood stabilizers, beta blockers, benzodiazepines<\/p>\n","protected":false},"template":"","class_list":["post-362287","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psychiatry","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/362287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/362287\/revisions"}],"predecessor-version":[{"id":362606,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/362287\/revisions\/362606"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=362287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}